Although these drugs indeed showed clinical benefits to HER2-positive breast cancer patients, acquired resistance is developed eventually and becomes a hurdle to be overcome (Nahta et al., 2009; Rexer and Arteaga, 2012; D'amato et al., 2015; Pernas and Tolaney, 2019). The gene discussed is ERBB2; the disease is breast cancer.